We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-6.73%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.47B
AUM Growth
-$295M
(-6.2%)
Cap. Flow
-$1.59B
Cap. Flow
% of AUM
-35.66%
Top 10 Holdings %
Top 10 Hldgs %
41.85%
Holding
141
New
13
Increased
10
Reduced
16
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$48.9M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$45.3M |
| 3 |
Pulmonx
LUNG
|
+$34.3M |
| 4 |
AdaptHealth
AHCO
|
+$25.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$23.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APR
Apria, Inc. Common Stock
APR
|
+$54M |
| 2 |
Glaukos
GKOS
|
+$41.9M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$40.1M |
| 4 |
Centene
CNC
|
+$36.9M |
| 5 |
Pacira BioSciences
PCRX
|
+$35.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.44% |
| 2 | Financials | 1.5% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $269M | 6.01% |
19,341,024
| – | – |
|
2
Viatris
VTRS
$20.1B
| $225M | 5.03% |
20,673,700
-100,300
| -0.5% | -$1.32M |
|
|
3
AdaptHealth
AHCO
$1.49B
| $187M | 4.18% |
11,650,072
+1,424,627
| +14% | +$25.6M |
|
|
4
Neurocrine Biosciences
NBIX
$17.2B
| $155M | 3.47% |
1,657,800
+279,855
| +20% | +$23.7M |
|
|
CMAX
5
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $122M | 2.72% |
528,703
-30,589
| -5% | -$6.35M |
|
|
6
Pulmonx
LUNG
$59.1M
| $91.7M | 2.05% |
3,695,341
+1,328,474
| +56% | +$34.3M |
|
|
SILK
7
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $88.9M | 1.99% |
2,153,712
+636,531
| +42% | +$22.4M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $82.3M | 1.84% |
4,891,996
+130,858
| +3% | +$1.93M |
|
9
Mirum Pharmaceuticals
MIRM
$7.25B
| $72.3M | 1.62% |
3,282,912
| – | – |
|
10
Kura Oncology
KURA
$964M
| $71M | 1.59% |
4,416,361
+902,605
| +26% | +$13M |
|
11
Organogenesis Holdings
ORGO
$337M
| $64.4M | 1.44% |
8,456,876
| – | – |
|
|
DCPH
12
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $51.7M | 1.16% |
5,580,456
| – | – |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $48.9M | 1.09% |
+465,000
| New | +$45.3M |
|
|
14
Centene
CNC
$32.8B
| $46.6M | 1.04% |
553,800
-450,000
| -45% | -$36.9M |
|
|
15
Gilead Sciences
GILD
$167B
| $45.5M | 1.02% |
+765,489
| New | +$48.9M |
|
16
Molina Healthcare
MOH
$11.7B
| $45M | 1.01% |
134,989
| – | – |
|
|
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
| $42.7M | 0.96% |
4,695,020
| – | – |
|
18
GeneDx Holdings
WGS
$1.88B
| $42.5M | 0.95% |
419,651
-3,586
| -0.8% | -$399K |
|
|
OMIC
19
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $41.7M | 0.93% |
220,401
-83,333
| -27% | -$19.3M |
|
20
Alphatec Holdings
ATEC
$1.31B
| $41.3M | 0.92% |
3,594,829
| – | – |
|
21
Edgewise Therapeutics
EWTX
$4.28B
| $38.2M | 0.85% |
3,933,137
| – | – |
|
22
Brookdale Senior Living
BKD
$3.58B
| $37.9M | 0.85% |
5,379,000
+1,104,192
| +26% | +$6.74M |
|
23
Cytokinetics
CYTK
$10.9B
| $35.1M | 0.78% |
952,703
+143,703
| +18% | +$5.11M |
|
24
The Oncology Institute
TOI
$535M
| $32.1M | 0.72% |
3,296,107
| – | – |
|
25
Pharvaris
PHVS
$2.44B
| $28.6M | 0.64% |
1,577,078
-4,253
| -0.3% | -$75K |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2022 Portfolio in Review
As of Q1 2022, Deerfield Management held 141 positions worth $4.47B, down 6.2% from $4.77B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management withdrew a net $1.59B in Q1 2022, closing 19 positions and reducing 16 holdings. Its most notable exit was Apria, Inc. Common Stock, an estimated $54M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 63% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $45.5M.
- Deerfield Management's largest Q1 2022 buy was Gilead Sciences: 765,489 shares worth $45.5M.
- Deerfield Management added most to Pulmonx in Q1 2022, an estimated $34.3M increase.
- Deerfield Management's biggest Q1 2022 reduction was Glaukos, cutting an estimated $41.9M.
- Deerfield Management fully exited Apria, Inc. Common Stock in Q1 2022, selling an estimated $54M.
- Deerfield Management's ten largest holdings make up 42% of its $4.47B portfolio in Q1 2022.
- Deerfield Management opened 13 new positions and closed 19 in Q1 2022.
- Deerfield Management's portfolio value fell 6.2% quarter-over-quarter to $4.47B.
Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.